MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Bristol-Myers Squibb Co.

Cerrado

SectorSalud

59.58 0.18

Resumen

Variación precio

24h

Actual

Mínimo

59.11

Máximo

60.13

Métricas clave

By Trading Economics

Ingresos

-1.1B

76M

Ventas

442M

12B

P/B

Media del Sector

14.05

63.778

BPA

1.67

Rentabilidad por dividendo

4.07

Margen de beneficio

0.616

Empleados

34,100

EBITDA

-1.9B

2.6B

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

+2.32% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

4.07%

2.39%

Próximas Ganancias

24 abr 2025

Fecha Próximo Dividendo

1 may 2025

Próxima Fecha de Ex Dividendo

4 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

311M

121B

Apertura anterior

59.4

Cierre anterior

59.58

Noticias sobre sentimiento de mercado

By Acuity

37%

63%

130 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Bristol-Myers Squibb Co. Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

11 mar 2025, 10:13 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

11 mar 2025, 10:13 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

6 feb 2025, 12:13 UTC

Ganancias

Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook

14 mar 2025, 09:30 UTC

Principales Noticias

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

11 mar 2025, 02:26 UTC

Adquisiciones, fusiones, absorciones

Abecma Is an Immunotherapy Indicated for Treatment of Relapsed or Refractory Multiple Myeloma >TSVT

11 mar 2025, 02:26 UTC

Adquisiciones, fusiones, absorciones

Stockholders Owning About 5.3% of 2seventy Bio Shares Have Agreed to Tender All Their Shares >TSVT

11 mar 2025, 02:26 UTC

Adquisiciones, fusiones, absorciones

2seventy Bio CEO: Rationale for Deal Clear, in Line With Focus on Unlocking Value of Abecma >TSVT

11 mar 2025, 02:23 UTC

Adquisiciones, fusiones, absorciones

2seventy Bio Stock Will No Longer Trade on Nasdaq After Closing of Deal, Expected in 2Q >TSVT

11 mar 2025, 02:22 UTC

Adquisiciones, fusiones, absorciones

2seventy Bio's Board Unanimously Recommends Stockholders Tender Shares in Offer >TSVT

11 mar 2025, 02:21 UTC

Adquisiciones, fusiones, absorciones

Bristol Myers Deal Represents 88% Premium to 2seventy Closing Price of $2.66 on March 7 >TSVT

11 mar 2025, 02:21 UTC

Adquisiciones, fusiones, absorciones

Bristol Myers to Acquire 2seventy Bio Shares at $5.00 Each in All-Cash Deal for Equity Value of About $286M >TSVT

11 mar 2025, 02:19 UTC

Adquisiciones, fusiones, absorciones

2seventy Bio Enters Into Definitive Agreement to Be Acquired by Bristol Myers Squibb

28 feb 2025, 12:00 UTC

Principales Noticias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6 feb 2025, 15:35 UTC

Ganancias

Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD

6 feb 2025, 13:56 UTC

Ganancias

Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%. -- IBD

6 feb 2025, 13:25 UTC

Principales Noticias
Ganancias

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6 feb 2025, 12:00 UTC

Ganancias

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

6 feb 2025, 11:59 UTC

Ganancias

Bristol-Myers Squibb 4Q Gross Margin 61.0% >BMY

6 feb 2025, 11:59 UTC

Ganancias

Bristol-Myers Squibb 4Q Rev $12.3B >BMY

6 feb 2025, 11:59 UTC

Ganancias

Bristol-Myers Squibb 4Q Net $72M >BMY

6 feb 2025, 11:59 UTC

Ganancias

Bristol-Myers Squibb 4Q EPS 4c >BMY

6 feb 2025, 11:59 UTC

Ganancias

Bristol-Myers Squibb 4Q Adj EPS $1.67 >BMY

6 feb 2025, 11:59 UTC

Ganancias

Bristol Myers Squibb: Expanding Existing Strategic Productivity Initiative to Include About $2B in Additional Annualized Cost Savings by the End of 2027 >BMY

6 feb 2025, 11:59 UTC

Ganancias

Bristol Myers Squibb 4Q International Revenue Rose 5% to $3.7B >BMY

6 feb 2025, 11:59 UTC

Ganancias

Bristol Myers Squibb 4Q U.S. Revenue Rose 9% to $8.6B >BMY

6 feb 2025, 11:59 UTC

Ganancias

Bristol Myers Squibb 4Q Legacy Portfolio Revenue $5.98B, Down 4% >BMY

6 feb 2025, 11:59 UTC

Ganancias

Bristol Myers Squibb: 4Q Growth Portfolio Revenue Primarily Due to Higher Demand for Reblozyl, Breyanzi, Camzyos, Yervoy and Opdualag >BMY

6 feb 2025, 11:59 UTC

Ganancias

Bristol Myers Squibb 4Q Rev $12.34B >BMY

6 feb 2025, 11:59 UTC

Ganancias

Bristol Myers Squibb: 4Q Legacy Portfolio Revenue Lower Vs Yr-Ago Primarily Due to Impact of Generics on Sprycel, Revlimid, Abraxane and Pomalyst, Partially Offset by Higher Demand for Eliquis >BMY

6 feb 2025, 11:59 UTC

Ganancias

Bristol Myers Squibb: 2025 Rev Outlook Reflects Near-Term Impact of Generics Across Revlimid, Pomalyst, Sprycel and Abraxane >BMY

Comparación entre iguales

Cambio de precio

Bristol-Myers Squibb Co. Esperado

Precio Objetivo

By TipRanks

2.32% repunte

Estimación a 12 meses

Media 60.93 USD  2.32%

Máximo 70 USD

Mínimo 37 USD

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bristol-Myers Squibb Co. Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

16 ratings

5

Comprar

10

Mantener

1

Vender

Puntuación técnica

By Trading Central

59.18 / 59.9Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

130 / 386 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.